If it's the same player then it could be one of the 2 substantial holders increasing their position, but I suspect there are other big players in the market like Vanguard , Blackrock and Goldman Sachs interested.
MSB/MESO have the first MESENCHYMAL STROMAL CELL approved FDA lab with an FDA approved product. That's a big first player advantage for a while.
All these big players have there fingers into any serious developing technology. So I think some of them may have decided to get their fingers into this pie, while it is still a small pie.
So it will be interesting watch MESO in the US markets overnight to see if there is some follow-up action. Today MSB closed at 3.35 (with 12.7m volume) and that makes the equivalent MESO (MSBx10) worth $US21. The equivalent volume with MESO would be 1.2m.
So if MESO trades about 1.2m volume and buying pressure pushes it up to the $US22 (that's about 3.57 for MSB), then they may have continued accumulating. And if they snap up shares in early trading in Australia in the range 3.35 to 3.57 they could add more to the kitty without overpaying.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)